Eric Benevich - 11 Sep 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: NBIX
Reported as of: 11 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Sep 2026, 17:02:46 UTC
Prior SEC filing: 10 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eric Benevich filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 15 Sep 2026.

Key facts

This page summarizes Eric Benevich's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Sep 2026, 17:02.

Change

Previous filing in this sequence was filed on 10 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643653 Primary reporting owner

BENEVICH ERIC

Relationship: Chief Commercial Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 15 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Award

Transaction value
Shares: +6,275
Change %: +9.7%
Price: $0.000000^*
Shares after: 70,683
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F1

NBIX transaction

Common Stock

Tax liability

Transaction value
Shares: -3,386
Change %: -4.8%
Price: $156.22^*
Shares after: 67,297
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

Footnote F2

Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.